Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine

Ischemic Heart Disease Clinical Trial

Official title:

Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00392964
• Other study ID #: ZSA2438CTIL
• Status: Completed
• Phase: N/A
• First received: October 25, 2006
• Last updated: April 10, 2007
• Start date: January 2006
• Est. completion date: November 2006

Study information

• Verified date: April 2007
• Source: Rambam Health Care Campus
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Israeli Health Ministry Pharmaceutical Administration
• Study type: Observational

Clinical Trial Summary

There is substantial, continuing, and unexplained rise in prescribing of proton pump inhibitors. It is unknown whether their use in practice has corresponded to their licensed indications.

Although the indications for H2RA or PPI administration in the treatment of acid-related diseases and the prevention of gastric mucosal damage have been well defined in the medical literature, the perception of benefit from their use frequently tends to be extrapolated to all patients in general, leading to an excessive consumption of these drugs in general practice.

To date, however, little has been published with regard to the overall use or misuse of these drugs in hospital populations in ischemic heart disease patients as a secondary prevention to Aspirin use.

We will undertake a 6-months retrospective survey (about 1200 patients) to evaluate the use of acid-suppressive medications in the general internal medicine ward of Rambam Hospital.

We will extract all records of prescribing of a proton pump inhibitor within Rambam Hospital computerized patients file program (Premetheuos) in period of half year, categorized and analyze them using statistical X2 test.

Description:

Dyspeptic symptoms are a common presenting complaint, and there is continuing debate about management. Acid suppressant drugs, the most potent of which are proton pump inhibitors, are often prescribed, and it has been suggested that proton pump inhibitors are probably too widely prescribed for minor symptoms, and the cost implications of this are clear. There is substantial, continuing, and unexplained rise in prescribing of proton pump inhibitors. It is unknown whether their use in practice has corresponded to their licensed indications.

Although the indications for H2RA or proton pump inhibitor administration in the treatment of acid-related diseases and the prevention of gastric mucosal damage have been well defined in the medical literature, the perception of benefit from their use frequently tends to be extrapolated to all patients in general, leading to an excessive consumption of these drugs in general practice.

In addition, Physicians, nowadays tend to prescribe proton pump inhibitors for cardiac patients who use aspirin as secondary prevention of their illness.

To date, however, little has been published with regard to the overall use or misuse of these drugs in hospital populations, or to the fall-out of hospital prescriptions in general practice and none has been published regarding its use in ischemic heart disease patients as a secondary prevention to Aspirin use.

We will undertake a 6-months retrospective survey (about 1200 patients) to evaluate the use of acid-suppressive medications in the general internal medicine ward of Rambam Hospital, a large teaching hospital in Northern Israel; as well as the appropriateness of their prescription to the licensed indications, while dividing them to subgroups of ischemic heart disease patients.

We will extract all records of prescribing of a proton pump inhibitor within Rambam Hospital computerized patients file program (Premetheuos) in period of half year, categorized and analyze them using statistical X2 test.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1200
• Est. completion date: November 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ischemic Heart Disease

Study Design

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal

Related Conditions & MeSH terms

• Coronary Artery Disease
• Heart Diseases
• Ischemic Heart Disease
• Myocardial Ischemia

Locations

Country	Name	City	State
Israel	Rambam Health Care Campus	Haifa
Israel	Rambam: Health Care Campus	Haifa

Sponsors (1)

Lead Sponsor	Collaborator
Rambam Health Care Campus

Country where clinical trial is conducted

Israel,